HistoSonics, the developer and manufacturer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its new therapy platform. Histotripsy of …
Trending at Lumira Ventures
Invest in BC Presented by Lumira Ventures: Life Sciences BC Announces Presenting Companies Pitching
VANCOUVER, British Columbia – Life Sciences British Columbia (LSBC) announces the 31 companies presenting to the 6th annual Invest in BC presented by Lumira Ventures on November 3 and 4, 2021. This virtual conference showcases a broad range of investor-ready …
OpSens Successfully Treats First Patients in Human Clinical Study for TAVR Procedure
QUEBEC, Quebec, October 13, 2021 – OpSens Inc. (TSX:OPS), a cardiology medical device company providing innovative product solutions based on its patented optical technology, is pleased to announce the commencement of the human clinical study utilizing the SavvyWire, and successful …
The Industry of Biotechnology is on the rise and Canadian LPs are waking up: Peter van der Velden and Anthony Mouchantaf (RBCx) discuss why on Tank Talks by Ripple Ventures
Over the years we have seen a surge in investor interest and deal making in biotech. Lumira Ventures General Partner and Managing Director, Peter van der Velden is joined by Anthony Mouchantaf, Director, Venture Capital at RBCx and Tank Talks …
Lumira Ventures invests in LQT Therapeutics US$19M Series A financing to advance lead compound through Phase 1
LQT Therapeutics, Inc. (LQTT) a pharmaceutical company pioneering the development of precision therapies for genetic heart diseases, today announced the successful completion of a US$19 million Series A financing. LQTT is advancing a series of in-licensed compounds discovered and developed by Sanofi …
BioTheryX Announces Appointments of Three New Members to its Board of Directors
BioTheryX, Inc., a clinical-stage company focused on creating life-saving medicines through targeted protein degradation, today announced the appointments of Nancy Miller-Rich, John A. Hohneker, M.D., and Diantha Duvall to its Board of Directors. “The wealth of biotech leadership and industry knowledge that Nancy, John, …
Fusion Pharmaceuticals Announces FDA Clearance Of IND For FPI-1966, An Investigational Radiopharmaceutical For The Treatment Of Head And Neck And Bladder Cancers Expressing FGFR3
HAMILTON, ON and BOSTON, July 28, 2021 — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) applications …
Satsuma Pharmaceuticals Announces First Subject Randomized in SUMMIT™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced randomization of …
Angelini Pharma and Lumira Ventures launch the Angelini Lumira Biosciences Fund (ALBF)
– Angelini Pharma will invest US$35 million and be the sole investor in this innovative fund – ALBF will invest in early-stage companies developing pharmaceuticals to treat central nervous system disorders and rare diseases – ALBF will complement Lumira’s US$220 …
Lumira Ventures Closes on US$255 Million of New Capital to Build Transformative Healthcare Companies
Oversubscribed Lumira Ventures IV to continue successful focus backing biotechnology and medtech companies in Canada and U.S. Companion strategic fund formed in partnership with international pharmaceutical company During the past 18 months Lumira Ventures completed 8 exit transactions and portfolio …
XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina
Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clinical safety data from the Phase 1 dose escalation Phase 2 clinical data readouts on safety and efficacy of XC001 anticipated in 2022 …
American Medical Association (AMA) issued the first ever, unique CPT code for histotripsy of the liver
HistoSonics, the developer and manufacturer of a non-invasive platform and novel sonic beam therapy called histotripsy, today announced that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT) code for histotripsy of the liver. Histotripsy of …
Antios Therapeutics and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection
Antios Therapeutics, Inc. and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination of Arbutus’ proprietary GalNAc delivered RNAi therapeutic, AB-729, Antios’ proprietary active site polymerase inhibitor …
Join Peter van der Velden for a talk on healthcare venture capital
Our Managing General Partner, Peter van der Velden will talk about his experience with healthcare venture capital in Canada and the United States. The interactive virtual investment event is hosted by HaloHealth on Thursday, June 24th at 7:30PM-9:30PM EST. If …
Fusion Pharmaceuticals Announces Preliminary Safety And Dosimetry Results From Its Single-Dose Portion Of The Phase 1 Study Of FPI-1434
Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity Imaging shows drug uptake across multiple tumor types Enrollment in multi-dosing cohorts continues Fusion also reported preclinical …